Nintx
Katia Sivieri, PhD, serves as the Head of Microbiome Research at Nintx since January 2022 and holds the position of Professor at UNIARA since August 2022. Additionally, Katia has been an Adjunct Professor at Universidade Anhanguera São Paulo since May 2019 and a Scientific Researcher at UNESP - Universidade Estadual Paulista "Júlio de Mesquita Filho" since January 2010, focusing on the development of a Dynamic Intestinal Model and the study of functional foods and bioactive substances. Previously, Katia was a Senior Project Coordinator at T.I.A. Brasil Tecnologia Industrial Aplicada from January 2018 to October 2021, where the emphasis was on developing new products and processes utilizing tangential filtration technology. Katia's academic credentials include a Postdoc in Molecular Biology from INRAE, a PhD in Food Technology, a Master's degree in Food Science from USP - Universidade de São Paulo, and a Bachelor's degree in Biology from Universidade Estadual Paulista Júlio de Mesquita Filho.
This person is not in any teams
Nintx
Originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants and microorganisms) into novel therapies, Nintx (Next Innovative Therapeutics) believes plant-based natural products bear huge potential to serve as a superb platform to modulate human biological targets and the microbiome concomitantly, affording therapies for multifactorial diseases (multi-target therapies). Nintx was founded by two experienced PhD scientists, Dr. Miller Freitas (CEO) and Dr. Cristiano Guimarães (CSO), who are the main executives of the company, and Mr. Stephani Saverio, MBA, a healthcare veteran who has been acting as a Non-Executive Board Member for the startup. Nintx is a startup with innovation as core business, right at the center of the strategy, heavily based on advanced technologies, coupled with the Brazilian biodiversity, the most biologically diverse in the world, to develop the next generation of therapies. Some of Nintx’s proprietary technologies include xGIbiomics®, which closely emulates the human gastrointestinal digestive system and microbiome, and GAIApath®, an artificial intelligence and analytics solution to map and select medicinal plants with the ability to modulate targets and the microbiome concomitantly. Nintx’s cutting-edge technologies and concepts will be key in the future development of multi-target therapies.